NL-OMON43825已完成不适用
Technology in Motion (TIM): Unobtrusive assessment of motor (dys)function - TIM
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 190
研究概览
简要总结
Trial ended prematurely
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •General: 18 years or older, male/female, have command of the Dutch language.
- •Additional for stroke: survivor of a cerebrovascular accident (stroke)
- •Additional for PD: Diagnosed with PD according to the UK PD Brain Bank criteria
- •Additional for patients with tremor: tremor of the hand and/or arm, having a scheduled visit for tremor assessment at the Clinical Neurophysiology outpatient clinic at LUMC.
- •Additional for healthy controls: normal function of both arms, normal gait and balance function, normal cognitive function (MoCA score > 26), normal or corrected to normal vision
排除标准
- •* additional neurological diseases and/or orthopedic problems interfering with hand/arm function or balance/gait function
- •* unable to comply with the protocol, i.e. insufficient general fitness or cognitive/communicative inability to understand instructions and participate in the measurement
- •* inability to walk with help of one person (for the *gait and balance* experiment only);Additional for stroke:
- •* <12 weeks after stroke
- •* established Hereditary Cerebral Hemorrhage With Amyloidosis - Dutch type (HCHWA-D)
- •* absence of any voluntary control of the paretic arm (for the *reaching and grasping* experiment only)
研究者
相似试验
已完成
不适用
Safety and Performance Evaluation of the AccuCinch Ventricular Repair System for the treatment of heart failure, with or without functional Mitral Regurgitation Due to Dilated Ischemic or Non-Ischemic Cardiomyopathydilation of heart left ventriclefunctional mitral regurgitation10019280Heart failureNL-OMON48568Ancora Heart, Inc.28
已完成
不适用
A Global Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancerscancer of stomachmaagkanker, kanker van de maag-slokdarmovergang, darm- en pancreaskanker1001799010017991stomach cancerNL-OMON56431Amgen10
已完成
3 期
A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable, Stage IIIB to IVM1c Melanoma (MASTERKEY-265)1) Unresectable stage IIIB to IVM1c melanoma2) Unremoved melanoma (type of skin cancer)10040900NL-OMON50729Amgen15
已完成
2 期
A Phase 2b/3 study to evaluate the safety, tolerability, and effects of livoletide (AZP-531), an unacylated ghrelin analog, on food-related behaviors in patients with Prader-Willi syndromePWSNL-OMON48225Millendo Therapeutics SAS23
撤回
3 期
ARTEMIS: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF).lung fibrosis10024967Idiopathic Pulmonary FibrosisNL-OMON35478Gilead Sciences6